Furthermore, the treatment landscape for the combination of ICI and vascular endothelial growth factor receptor (VEGFR) inhibitor for EMPD remains underexplored, particularly there has been substantial evidence that the combination has a significant synergistic anticancer effect in various kinds of solid tumors.9 Research indicates that combining carelizumab, with rivoceranib, significantly decreases peripheral blood regulatory T cell (Treg) levels and increases the effector T cell (Teff) to Treg ratio. This evidence concerns the gene KDR and extramammary Paget disease.